Skip to main content
. 2017 Nov 21;70(1):40–48. doi: 10.1002/art.40336

Figure 4.

Figure 4

Serum trough concentration (Ctrough) of SB5 and reference adalimumab (ADA) at week 24 among patients in each treatment group (A) and among subsets of antidrug antibody–positive patients and antidrug antibody–negative patients within each treatment group (B). Bars show the mean ± SD at each time point.